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Summary
Background The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include disease-causing 
serotypes that are important in low-income and middle-income countries. Vaccine eﬀ ectiveness estimates are scarce 
in these settings. South Africa replaced PCV7 with PCV13 in 2011 using a 2 + 1 schedule. We aimed to assess the 
eﬀ ectiveness of two or more doses of PCV13 against invasive pneumococcal disease in children with HIV infection 
and in those not infected with HIV.
Methods Cases of invasive pneumococcal disease in children aged 5 years or younger were identiﬁ ed through national 
laboratory-based surveillance. Isolates were serotyped with the Quellung reaction or PCR. We sought in-hospital 
controls for every case, matched for age, HIV status, and study site. We aimed to enrol four controls for every case not 
infected with HIV and six controls for every case with HIV infection (case-control sets). With conditional logistic 
regression, we calculated vaccine eﬀ ectiveness as a percentage, with the equation 1 – [adjusted odds ratio for 
vaccination] × 100. We included data from an earlier investigation of PCV7 to assess vaccine eﬀ ectiveness in children 
exposed to but not infected with HIV and in malnourished children not infected with HIV.
Findings Between January, 2012, and December, 2014, we enrolled children aged 16 weeks or older to our study: 
240 were cases not infected with HIV, 75 were cases with HIV infection, 1118 were controls not infected with HIV, 
and 283 were controls with HIV infection. The eﬀ ectiveness of two or more doses of PCV13 against PCV13-serotype 
invasive pneumococcal disease was 85% (95% CI 37 to 96) among 11 case-control sets of children not infected with 
HIV and 91% (–35 to 100) among three case-control sets of children with HIV infection. PCV13 eﬀ ectiveness among 
26 case-control sets of children not infected with HIV was 52% (95% CI –12 to 79) against all-serotype invasive 
pneumococcal disease and 94% (44 to 100) for serotype 19A. Vaccine eﬀ ectiveness against PCV7-serotype 
invasive pneumococcal disease was 87% (95% CI 38 to 97) in children exposed to HIV but uninfected and 90% 
(53 to 98) in malnourished children not infected with HIV.
Interpretation Our results indicate that PCV13 in a 2 + 1 schedule is eﬀ ective for preventing vaccine-type 
pneumococcal infections in young children not infected with HIV, including those who are malnourished or who 
have been exposed to HIV. Although the point estimate for PCV13 vaccine eﬀ ectiveness in children infected with 
HIV was high, it did not reach signiﬁ cance, possibly because of the small sample size. These ﬁ ndings support 
recommendations for widespread use of pneumococcal conjugate vaccine in low-income and middle-income 
countries.
Funding Gavi, The Vaccine Alliance.
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Introduction
Immunisation with pneumococcal conjugate vaccine is 
an important strategy to reduce global childhood mortality. 
Few quantitative results are available for the eﬀ ect of this 
vaccine in low-income and middle-income countries 
because it has not been in use for long and few clinical 
studies are underway.1,2 Policy makers in countries still 
considering introduction of pneumococcal conjugate 
vaccine, particularly those in Africa, might be inﬂ uenced 
by the eﬀ ectiveness of the vaccine in routine-use settings. 
More than 50% of an estimated 541 000 global deaths due 
to pneumococcus in 2008 occurred in sub-Saharan Africa.3 
HIV infection and in-utero exposure to HIV not resulting 
in infection are important risk factors for development 
of pneumococcal disease; approximately 20% of deaths 
caused by pneumococcal infection in children younger 
than 5 years in sub-Saharan Africa were related to HIV 
in 2000.3
The seven-valent pneumococcal conjugate vaccine 
(PCV7)—the ﬁ rst vaccine of its type to be licensed for 
routine use—has been replaced globally by higher valency 
vaccines (PCV10 and PCV13); these newer vaccines were 
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See Online for appendix designed to include a larger proportion of serotypes that 
cause disease in low-income and middle-income settings. 
Although the vaccine eﬀ ectiveness of PCV7 has been 
shown in several settings,4,5 and many studies have been 
published of the eﬀ ect of PCV7 and PCV13 (as shown on 
VIEW-hub), the only case-control studies to assess PCV13 
eﬀ ectiveness are from the UK and the USA.6–8 Data for 
eﬀ ectiveness of PCV13 are needed from middle-income 
or low-income countries and nations with a high 
prevalence of HIV.2
PCV7 was introduced into the South African routine 
 immunisation programme in April, 2009, using a novel 
2 + 1 vaccination schedule (ﬁ rst two doses given at 
age 6 weeks and age 14 weeks, with an additional dose at 
age 9 months) without catch-up.9 PCV13 began to replace 
PCV7 in June, 2011, administered in the same schedule, 
and by August, 2011, approximately 80% of facilities had 
switched. A limited, single-dose, catch-up campaign 
among children aged 18 months to 3 years was undertaken 
in 2011. In 2010, before introduction of PCV13, 
82% (530/650) of cases of invasive pneumococcal disease 
in children younger than 5 years were caused by serotypes 
in PCV13.10 HIV prevalence in South African pregnant 
women was consistently around 30% from 2010 to 2012;11 
however, access to interventions for prevention of mother-
to-child HIV transmission was increased for pregnant 
women with HIV infection (estimated mother-to-child 
transmission rate of 2·4% in 2012) during this period.12
We aimed to estimate the eﬀ ectiveness of two or more 
doses of PCV13 against invasive pneumococcal disease 
caused by PCV13 serotypes in children with HIV 
infections and in those not infected with HIV who were 
eligible to have received PCV13. In secondary analyses, 
we aimed to estimate the eﬀ ectiveness of two or more 
doses of PCV13 or PCV7 against the seven serotypes in 
PCV7 in children with HIV infection and in those not 
infected with HIV, in malnourished children not 
infected with HIV, and in those exposed to HIV but 
not infected—groups known to be at high risk for 
pneumococcal disease.
Methods
Study population and study design
We did a matched case-control study at 24 sentinel 
surveillance hospitals participating in the Group for 
Enteric, Respiratory and Meningeal Disease Surveillance 
in South Africa (GERMS-SA) national, laboratory-based, 
active surveillance programme,13 with continuous 
For more on the VIEW-hub 
platform see http://view-hub.org
Research in context
Evidence before this study
We searched PubMed for reports published before April 30, 2016, 
with the terms “13-valent pneumococcal vaccine” OR “13-valent 
pneumococcal conjugate vaccine” AND “eﬀ ectiveness”, “eﬃ  cacy”, 
“impact”, OR “invasive pneumococcal disease”. We searched for 
studies that assessed the eﬀ ectiveness of the 13-valent 
pneumococcal conjugate vaccine (PCV13) against invasive 
pneumococcal disease in children younger than 5 years, using a 
case-control approach. We identiﬁ ed several reports of the eﬀ ect 
of the pneumococcal conjugate vaccine but only three in which 
results were reported of case-control studies of PCV13 
eﬀ ectiveness. Two studies were from the UK, in which the indirect 
cohort method was used, and one was from the USA, in which a 
matched case-control approach was used. No studies of the 
eﬀ ectiveness of PCV13 were retrieved from low-income or 
middle-income countries or from countries with high prevalence 
of HIV, and our search did not identify any studies in which PCV13 
eﬀ ectiveness was assessed in a schedule aligned with WHO’s 
recommended Expanded Programme on Immunisation (EPI). 
Vaccine eﬀ ectiveness point estimates against invasive 
pneumococcal disease caused by serotypes included in the vaccine 
were 75% or greater for two or more doses of PCV13 in the UK 
study and 86% for one or more dose in the US study. One dose of 
PCV13 administered in children older than 1 year was also 
eﬀ ective in both the UK and US studies. In the report from the UK, 
greater than 70% eﬀ ectiveness of PCV13 was shown against all 
individual serotypes assessed, except serotypes 3 and 19A. In the 
US study, 80% or greater eﬀ ectiveness of PCV13 was noted 
against serotypes 3, 7F, and 19A.
Added value of this study
We did a case-control study of PCV13 eﬀ ectiveness against 
invasive pneumococcal disease in children not infected with HIV 
and in those with HIV infection in a middle-income African 
country. PCV13 was eﬀ ective against PCV13-serotype invasive 
pneumococcal disease in children not infected with HIV when 
implemented in a 2 + 1 schedule aligned with WHO’s 
recommended EPI schedule. Furthermore, two or more doses of 
PCV13 were eﬀ ective against serotype 19A, an important cause 
of replacement pneumococcal disease globally. Although the 
point estimate for vaccine eﬀ ectiveness in children infected 
with HIV was high, it did not reach signiﬁ cance, possibly 
because of the small sample size.
Implications of all the available evidence
Our study supports the recommendation for widespread use of 
pneumococcal conjugate vaccine in low-income and 
middle-income countries. Combining data from our study with 
those from a previous study of PCV7 eﬀ ectiveness showed that 
two or more doses of PCV7 or PCV13 were eﬀ ective against 
PCV7-serotype invasive pneumococcal disease in children 
exposed to but not infected with HIV and in malnourished 
children not infected with HIV. These are two of the most 
important subgroups of children at high risk for serious 
pneumococcal disease in low-income and middle-income 
settings with a high prevalence of HIV. These data, when 
combined with disease rate and vaccine coverage data, might 
enable estimation of expected vaccine eﬀ ectiveness in advance 
of vaccine introduction in other settings. 
Articles
www.thelancet.com/lancetgh   Vol 5   March 2017 e361
enrolment beginning during the period of PCV7 use 
(children born from February, 2009, to the end of July, 
2011) through to the PCV13 period (children born from 
August, 2011). Study design and methods of the PCV7 
assessment of vaccine eﬀ ectiveness have been published 
previously.4 For the PCV13 assessment of vaccine 
eﬀ ectiveness, we used the same protocol as for the PCV7 
analysis but with minor modiﬁ cations and analysis 
periods, detailed below.
We deﬁ ned a case as an episode of illness in an 
individual with Streptococcus pneumoniae (pneumococcus) 
from normally sterile-site specimens—eg, cerebrospinal 
ﬂ uid (CSF), blood, pleural ﬂ uid, and joint ﬂ uid. We judged 
children eligible for study enrolment if they were: aged 8 
weeks or older at specimen collection (cases) or admission 
(controls); resident in South Africa from age 6 weeks; and 
in the birth cohort eligible to receive at least one dose of 
pneumococcal conjugate vaccine through the Expanded 
Programme on Immun isation (EPI).4 Exclusion criteria 
for cases and controls included absence of veriﬁ ed HIV 
status, previous enrolment as a case, or enrolment of a 
twin. We restricted subgroups for PCV13 analysis to 
infants born from August, 2011 (deﬁ ned as the PCV13 
period), based on calendar time of PCV13 availability.
During the period of use of PCV13, we aimed to enrol 
four controls for every case not infected with HIV and 
six controls for every case with HIV infection (case-
control sets). We matched controls to cases by date of 
birth (within 1 calendar month for children aged 
12 months or younger and within 2 calendar months for 
children older than 12 months), surveillance site, and 
HIV status. We judged children eligible for enrolment as 
a control if they were admitted to or attending the casualty 
or outpatient department at the same hospital as the case. 
We excluded children as potential controls if they had a 
diagnosis of invasive pneumococcal disease, pneumonia, 
or another non-diarrhoeal vaccine-preventable disease. 
Every day we compiled lists of potential controls 
systematically from hospital registers. We attempted to 
enrol controls as soon as possible after the case-admission 
date. We only judged hospitalised controls eligible for 
enrolment if they were identiﬁ ed within 72 h of their 
admission. We enrolled controls infected with HIV from 
neighbouring HIV clinics, selected as clinics that did not 
actively review vaccination status or oﬀ er immunisation 
with the pneumococcal conjugate vaccine.
We obtained written informed consent from parents or 
guardians of cases and controls. Institutional review 
boards at the University of the Witwatersrand, the 
24 surveillance sites, the US Centers for Disease Control 
and Prevention (CDC), and the Johns Hopkins 
Bloomberg School of Public Health approved the study. 
Procedures
We sent pneumococcal isolates to the National Institute 
for Communicable Diseases (NICD) in Johannesburg 
for analysis. We conﬁ rmed isolates as pneumococcus 
with standardised methods.14 We used the Quellung 
reaction to serotype isolates, using speciﬁ c antisera, 
including serotypes 6A, 6B, 6C, and 6D (Statens 
Serum Institut, Copenhagen, Denmark). We conﬁ rmed 
serotypes in samples of CSF from culture-negative but 
clinically suspicious cases, as well as isolates that lost 
viability (n=47 in the PCV13 period), with real-time 
lytA PCR.14 To serotype these samples, we used a PCR 
serotyping assay consisting of 11 duplex reactions, with 
an additional primer or probe set for serotype 6C or 
6D.15 We deﬁ ned PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 
and 23F), PCV13 additional serotypes (1, 3, 5, 6A, 7F, 
and 19A), and non-vaccine serotypes to be mutually 
exclusive. We deﬁ ned clinical syndromes hierarchically 
as meningitis, bacteraemic pneumonia, bacteraemia 
without focus, and other.
Data collection by interview and record review, and 
procedures for HIV testing, have been described 
previously.4 We gathered information on exposures such 
as vaccination status and other potential confounders 
from 1 month preceding the date of pneumococcal 
specimen collection (the reference period) from cases 
and their matched controls. We did HIV testing by ELISA 
for children aged 18 months or older and by qualitative 
HIV DNA PCR for children younger than 18 months. 
We assessed severe immunosuppression based on the 
percentage of CD4+ cells in the total lymphocyte count 
(measured by ﬂ ow cytometry), according to WHO 
categories.15,16 We classiﬁ ed children as being exposed to 
HIV but not infected if they had documented HIV-
negative status but their mother was HIV-positive. 
We categorised children as malnourished if they had a 
weight-for-age Z score less than –2 (using 2009 WHO 
child growth standards, adjusting for prematurity for 
those born <37 weeks’ gestation) or had nutritional 
oedema.4,17 We sought a written immunisation history for 
all cases and controls from patient-held immunisation 
records and, if needed, vaccination records at health 
facilities. If the primary caregiver said the child had never 
been vaccinated, we recorded the child as unvaccinated.
Statistical analysis
We assumed vaccine eﬀ ectiveness against PCV13 
serotypes to be 80% in children not infected with HIV 
and 65% in those with HIV infection.4,18 For the matched 
analysis, we assumed a case-control PCV13 vaccination 
correlation of 0·2. Assuming vaccine coverage of 75% at 
a signiﬁ cance level (α) of 0·05 and a power of 0·80, with 
a 4:1 match of controls to cases for children not infected 
with HIV and a 6:1 match for those with HIV infection, 
we needed to enrol 19 children (cases) with PCV13 
serotype disease not infected with HIV and 76 controls, 
and 40 children with HIV infection and 240 controls.
We present baseline and patients’ enrolment data for the 
PCV13 period (ie, children born from August, 2011, 
onwards); details for the PCV7 period (ie, children 
born from February, 2009, to July, 2011) have been 
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published previously.4 We used data from GERMS-SA to 
compare the characteristics of enrolled and non-enrolled 
children (cases) with invasive pneumococcal disease in 
the PCV13 period. We estimated the matched odds ratio of 
vaccination (vs no vaccination) in cases and controls, 
controlling for confounders, using conditional logistic 
regression. We counted doses of pneumococcal conjugate 
vaccine only if they were received 14 days or more before 
the pneumococcal specimen collection date.
Potential confounders that altered the odds ratio of 
immunisation with pneumo coccal conjugate vaccine by 
more than 10 percentage points were included in multi-
variable models for analyses. Although no standard cutoﬀ  
is available for identiﬁ cation of confounders, we opted to 
use 10% as a cutoﬀ  that would detect meaningful 
alterations in the odds ratio while maintaining a fairly 
parsimonious model. We included one set of confounders 
for children not infected with HIV in the PCV13 period 
and a second set for those without HIV infection in the 
combined PCV7 and PCV13 period, to ease comparisons 
of various estimates for vaccine eﬀ ectiveness within each 
group. We did the same for children infected with HIV. 
We have presented adjustment variables for each analysis 
as footnotes to the tables. We checked for collinearity and 
two-way interactions in all ﬁ nal models.
We calculated vaccine eﬀ ectiveness as a percentage, 
with the equation 1 – [adjusted matched odds ratio] × 100. 
We judged p values less than 0·05 signiﬁ cant. Analyses 
were done with Stata statistical software (version 14.1).
For each univariate analysis, we used all available case 
information. In the multivariable model, we excluded 
patients with missing data for included variables (data 
were >90% complete for all variables). For the main 
analyses, the group of children not infected with HIV 
included all those documented as not infected, including 
those who were exposed to HIV in utero. We assessed 
vaccine eﬀ ectiveness in subgroups for which cases 
and controls were not matched (eg, HIV exposure, 
malnutrition) by inclusion of an interaction term in 
the multivariable model. For the primary objective 
(eﬀ ectiveness of two or more doses of PCV13 against 
invasive pneumococcal disease caused by PCV13 
serotypes), we included in the analysis all children aged 
16 weeks or older and born in the PCV13 period. For 
the analysis of vaccine eﬀ ectiveness in subgroups 
(eg, malnourished), as well as some analyses of diﬀ erent 
schedules (appendix p 5), we included children born in 
both the PCV7 and PCV13 periods to increase statistical 
power for stratiﬁ ed analyses. For the analysis of 
eﬀ ectiveness of one booster dose of PCV13, we included 
all children eligible to receive PCV13 booster and older 
than 41 weeks of age.
For analysis of PCV13-speciﬁ c endpoints, we included 
individuals born after August, 2011. For secondary 
 Not infected with HIV Infected with HIV
Cases (n=240) Controls (n=1118) p value Cases (n=75) Controls (n=283) p value
Demographics
Age (weeks) 37 (17–106) 36 (17–99) 0·667 48 (21–107) 53 (20–109) 0·586
Male sex 144/240 (60%) 668/1118 (60%) 0·943 39/75 (52%) 157/283 (55%) 0·591
Female sex 96/240 (40%) 450/1118 (40%) ·· 36/75 (48%) 126/283 (45%) ··
Not black ethnic origin 35/240 (15%) 185/1118 (17%) 0·454 4/75 (5%) 16/283 (6%) 0·914
Risk factors
Malnutrition* 84/240 (35%) 341/1114 (31%) 0·184 52/75 (69%) 132/282 (47%) 0·001
Low birthweight (<2500 g) 54/233 (23%) 202/1111 (18%) 0·078 15/72 (21%) 60/280 (21%) 0·912
Preterm (<37 completed weeks) 45/223 (20%) 140/1054 (13%) 0·008 14/67 (21%) 45/262 (17%) 0·479
Underlying disorders (not HIV)† 62/240 (26%) 151/1118 (14%) <0·0001 6/75 (8%) 17/283 (6%) 0·531
Smoking exposure 51/238 (21%) 192/1117 (17%) 0·122 10/75 (13%) 48/283 (17%) 0·448
Day care attendance 36/237 (15%) 161/1114 (14%) 0·770 7/75 (9%) 37/281 (13%) 0·370
Number of children aged <5 years 
in household
·· ·· 0·051 ·· ·· 0·060
0 130/236 (55%) 688/1115 (62%) ·· 48/75 (64%) 189/282 (67%) ··
1–2 94/236 (40%) 397/1115 (36%) ·· 23/75 (31%) 90/282 (32%) ··
≥3 12/236 (5%) 30/1115 (3%) ·· 4/75 (5%) 3/282 (1%) ··
Previous hospital admission 
(in past 12 months)
84/341 (35%) 257/1118 (23%) <0·0001 43/75 (57%) 114/283 (40%) 0·008
Upper-respiratory-tract infection in 
reference period‡
108/236 (46%) 357/1110 (32%) <0·0001 50/73 (68%) 87/280 (31%) <0·0001
Breastfed§ 175/227 (77%) 831/1058 (79%) 0·630 50/71 (70%) 216/276 (78%) 0·164
(Table 1 continues on next page)
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 Not infected with HIV Infected with HIV
Cases (n=240) Controls (n=1118) p value Cases (n=75) Controls (n=283) p value
(Continued from previous page)
Socioeconomic factors
Residence in an informal dwelling 57/238 (24%) 270/1118 (24%) 0·948 23/75 (31%) 79/283 (28%) 0·639
Crowding (people per room) .. .. 0·098 .. .. 0·870
≤2 99/235 (42%) 555/1115 (50%) .. 34/75 (45%) 133/282 (47%) ..
3–4 100/235 (43%) 419/1115 (38%) .. 30/75 (40%) 114/282 (40%) ..
5–30 36/235 (15%) 141/1115 (13%) .. 11/75 (15%) 35/282 (12%) ..
Maternal education .. .. 0·163 .. .. 0·709
No secondary 27/237 (11%) 103/1117 (9%) .. 11/73 (15%) 36/282 (13%) ..
Some secondary 133/237 (56%) 581/1117 (52%) .. 45/73 (62%) 168/282 (60%) ..
Completed secondary 77/233 (32%) 433 (39%) .. 17/73 (23%) 78/282 (28%) ..
Household has a car 223/1118 (20%) 39/240 (16%) 0·188 13/75 (17%) 30/283 (11%) 0·111
HIV-related factors
HIV exposed 53/235 (23%) 316/1112 (28%) 0·067 NA NA ..
HIV clinic attendance NA NA .. 14/68 (21%) 201/274 (73%) <0·0001¶
HIV stage (WHO classiﬁ cation) .. .. .. .. .. 0·036
1 NA NA .. 6/70 (9%) 64/273 (23%) ..
2 NA NA .. 2/70 (3%) 11/273 (4%) ..
3 NA NA .. 33/70 (47%) 114/273 (42%) ..
4 NA NA .. 29/70 (41%) 84/273 (31%) ..
Receiving antiretroviral therapy NA NA .. 27/69 (39%) 173/278 (64%) <0·0001
Severe immunosuppression|| NA NA .. 29/34 (85%) 99/175 (57%) 0·002
Receiving trimethoprim-
sulfamethoxazole prophylaxis
3/236 (1%)** 36/1108 (3%)** 0·095 26/74 (35%) 173/283 (61%) <0·0001
Current tuberculosis treatment 8/237 (3%) 14/1112 (1%) 0·020 13/75 (17%) 46/282 (16%) 0·832
Vaccines received
Hepatitis B at 16 weeks 181/240 (75%) 952/1118 (85%) <0·0001 60/75 (80%) 249/283 (88%) 0·074
DTP vaccine at 16 weeks 157/240 (65%) 863/1118 (77%) <0·0001 52/75 (69%) 229/283 (81%) 0·030
PCV13
No doses 11/240 (5%) 27/1118 (2%) Reference 3/75 (4%) 7/283 (2%) Reference
One dose 50/240 (21%) 139/1118 (12%) 0·804 14/75 (19%) 24/283 (8%) 0·720
Two doses 106/240 (44%) 549/1118 (49%) 0·018 33/75 (44%) 119/283 (42%) 0·583
Three or more doses 73/240 (30%) 403/1118 (36%) <0·0001 25/75 (33%) 133/283 (47%) 0·154
Age at receipt of PCV13 doses (weeks)
Dose 1 6 (5–14) 6 (5–13) 0·969 6 (5–26) 6 (5–14) 0·079
Dose 2 14 (13–28) 15 (13–26) 0·332 16 (13–40) 15 (13–39) 0·027
Dose 3 40 (38–46) 39 (38–49) 0·539 40 (32–68) 39 (35–54) 0·382
Dose 4 44 (44–44) 36 (36–36) 0·317 0 42 (42–42) ..
Inﬂ uenza vaccine 3/238 (1%) 5/1114 (<1%) 0·138 2/74 (3%) 13/281 (5%) 0·464
Data are number of patients/total number (%) or median (IQR). NA=not applicable. DTP=diphtheria, tetanus, pertussis. PCV13=13-valent pneumococcal conjugate vaccine. 
*Weight <80% of expected for age, adjusted for prematurity or oedema. †Asplenia, including asplenia or sickle-cell anaemia; chronic illness, including chronic lung disease, 
renal disease, liver disease, cardiac disease, and diabetes; other immunocompromising disorders (excluding HIV), including organ transplant, primary immunodeﬁ ciency, 
immunotherapy, and malignant disease; and other risk factors, including head injury with possible cerebrospinal ﬂ uid leak, neurological disorders, burns, and chromosomal 
abnormalities. ‡Reference period is 1 month preceding the date of pneumococcal specimen collection in cases. §Breastfed in the ﬁ rst 4 months of life. ¶Controls were 
recruited in part at HIV clinics that did not oﬀ er pneumococcal conjugate vaccine immunisation. ||Based on CD4+ percentage of total lymphocyte cell count, according to 
WHO categories, using the closest available CD4+ lymphocyte count 3 months before or after the reference period.16 **HIV-exposed but uninfected infants might be oﬀ ered 
trimethoprim-sulfamethoxazole prophylaxis.
Table 1: Characteristics of cases and controls aged 16 weeks or older who were eligible to receive PCV13 through the routine immunisation programme in 
South Africa (born after August, 2011)
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analyses, in which we assessed vaccine eﬀ ectiveness 
against PCV7 serotypes individually or within subgroups 
(eg, children not infected with HIV and malnourished or 
exposed to HIV in utero), we included data gathered 
since the start of the assessment of PCV7 vaccine 
eﬀ ectiveness (ie, infants born from February, 2009, 
onwards).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between March, 2010, and December, 2014, we identiﬁ ed 
762 eligible children with invasive pneumococcal disease 
aged 16 weeks or older, of whom 36 were excluded from the 
analysis (appendix p 3). Of 726 enrolled children (cases), 
315 (43%) were enrolled in the PCV13 period: 240 (76%) of 
these were not infected with HIV and 75 (24%) had HIV 
infection (table 1). The median age of the 315 enrolled 
children (cases) eligible to have received two or more 
PCV13 doses was 39 weeks (IQR 18–107). 183 (58%) of 
315 children were boys and 314 (100%) were hospitalised. 
The most common clinical disorders among these children 
were bacteraemic pneumonia (146/315 [46%]), meningitis 
(103/315 [33%]), and bacter aemia without focus (48/315 
[15%]). Enrolled and non-enrolled cases did not diﬀ er by 
age group, ethnic origin, sex, HIV infection status, 
specimen type, or province (data not shown).
Among 240 children (cases) not infected with HIV 
aged 16 weeks or older in the PCV13 period, 24 (10%) had 
invasive pneumococcal disease caused by PCV7 serotypes 
and 16 (67%) of these 24 children had received two or 
more doses of PCV13 (ﬁ gure, A). In an additional 
28 (11%) children, their invasive pneumococcal disease 
was due to the additional serotypes included in PCV13, 
and 14 (50%) of these 28 children had received two or 
more doses of PCV13. 164 (68%) children had invasive 
pneumococcal disease caused by non-vaccine serotypes. 
Among 75 children (cases) with HIV infection aged 
16 weeks or older in the PCV13 period, eight (11%) had 
PCV7-type invasive pneumococcal disease and six (75%) 
of these eight children had received two or more doses of 
PCV13 (ﬁ gure, B). For an additional 13 (17%) children, 
their invasive pneumococcal disease was due to the 
additional serotypes included in PCV13, and seven (54%) 
of these 13 children had received two or more doses of 
PCV13. 48 (64%) children had invasive pneumococcal 
disease caused by non-vaccine serotypes.
Between March, 2010, and March, 2015, 5135 eligible 
age-matched children were identiﬁ ed as potential 
controls, of whom 1926 were excluded from the analysis 
(appendix p 4). The remaining 3209 controls were 
included, of whom 1401 were enrolled in the PCV13 
period: 1118 were not infected with HIV and 283 had 
HIV infection. The median number of controls per case 
in the PCV13 period was four (IQR 4–5) for children not 
infected with HIV and three (2–6) for those with HIV 
infection. The median interval between specimen 
collection in children (cases) and enrolment of controls 
was 34 days (IQR 4–201) for controls not infected with 
HIV and 105 days (12–321) for controls with HIV 
infection (p=0·0001). Of 1118 controls not infected with 
HIV aged 16 weeks or older, 417 (37%) had a diagnosis of 
diarrhoea, 101 (9%) had diarrhoea and malnutrition, 
104 (9%) had malnutrition alone, 108 (10%) had a 
surgical diagnosis, 69 (6%) had febrile seizures, and 
319 (29%) had another diagnosis. Of 283 controls with 
HIV infection aged 16 weeks or older, 203 (72%) were 
enrolled during a scheduled HIV clinic visit, 39 (14%) 
had malnutrition alone, 18 (6%) had diarrhoea alone, 
16 (6%) had a diagnosis of diarrhoea and malnutrition, 
and seven (2%) had another diagnosis. Controls not 
infected with HIV and those with HIV infection aged 
16 weeks or older and enrolled in the PCV13 period were 
similar to their respective cases in age, sex, and ethnic 
origin but diﬀ ered with respect to other characteristics 
(table 1). Overall, 1204 (86%) of 1401 controls and 
237 (75%) of 315 cases aged 16 weeks or older had 
received two or more doses of pneumococcal conjugate 
vaccine.
Among children not infected with HIV aged 16 weeks 
or older (ie, after the primary vaccine series at age 6 and 
14 weeks) and enrolled in the PCV13 period, the 
adjusted vaccine eﬀ ectiveness of two or more doses of 
PCV13 was 85% (95% CI 37 to 96) against invasive 
pneumococcal disease caused by PCV13 serotypes and 
92% (40 to 99) against disease caused only by the six 
serotypes in PCV13 additional to those in PCV7 
(table 2). The adjusted vaccine eﬀ ectiveness of PCV13 
was 52% (–12 to 79) against all-serotype invasive 
pneumococcal disease, but this ﬁ nding was not 
signiﬁ cant. PCV13 was not eﬀ ective against non-PCV13 
serotype disease (15%, –189 to 75).
Among children not infected with HIV and enrolled 
over the whole study period (born from February, 2009, 
onwards), the adjusted vaccine eﬀ ectiveness of two or 
more doses of PCV7 or PCV13 was 78% (95% CI 46 to 91) 
against PCV7-serotype invasive pneumococcal disease 
(table 3). The eﬀ ectiveness was similar for two doses 
alone, or two primary doses of PCV7 or PCV13 plus a 
9-month dose of PCV7 or PCV13 (appendix p 5).
Furthermore, in children who were malnourished, 
adjusted vaccine eﬀ ectiveness of this schedule against 
PCV7-serotype invasive pneumococcal disease was 90% 
(95% CI 53 to 98), and in children exposed in utero to 
HIV it was 87% (38 to 97), which is similar to the adjusted 
vaccine eﬀ ectiveness noted in children without these 
conditions (table 3). No protection was noted against 
PCV7-serotype invasive pneumococcal disease from one 
dose of PCV7 or PCV13 given at about 6 weeks (vaccine 
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Figure: Bar chart showing the serotype of invasive pneumococcal disease and vaccination status of children eligible to receive PCV13 through the routine 
immunisation programme in South Africa (born after August, 2011)
Bars show the number of children aged 16 weeks or older (A) not infected with HIV (total n=240) and (B) infected with HIV (total n=75), and the number of doses of 
PCV13 received. *Not subtyped further. †Other non-vaccine serotype conﬁ rmed with PCR. ‡Unknown serotypes occurred either because an isolate was not available 
or because only serogroups could be ascertained with PCR. 
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eﬀ ectiveness 1%, 95% CI –141 to 59), based on 
information from 34 discordant sets (ie, case-control sets 
in which at least one control diﬀ ers from the case with 
respect to PCV13 vaccination status; appendix p 5). Too 
few children older than 9 months received one dose of 
PCV13 after priming with PCV7, so we could not evaluate 
this schedule’s eﬀ ectiveness against PCV13 additional 
serotypes (appendix p 6).
Among children not infected with HIV aged 16 weeks 
or older and enrolled over the whole study period, who 
had received either PCV7 or PCV13, adjusted vaccine 
eﬀ ectiveness against invasive pneumococcal disease 
caused by individual serotypes in both PCV7 and PCV13 
was 94% (95% CI 44 to 100) for serotype 14 and 97% 
(52 to 100) for serotype 23F (appendix p 7). Vaccine 
eﬀ ectiveness for serotypes 6B and 19F was low, although 
the numbers of children (cases) contributing to these 
analyses were small. Restricted to the PCV13 period, 
the adjusted vaccine eﬀ ectiveness against additional 
individual serotypes in PCV13 (not in PCV7) was only 
signiﬁ cant for serotype 19A (appendix p 8); serotypes 3, 
6A, and 7F could not be assessed.
Among children with HIV infection aged 16 weeks or 
older and enrolled in the PCV13 period, the adjusted 
vaccine eﬀ ectiveness of two or more doses of PCV13 was 
91% (95% CI –35 to 100) against PCV13-serotype invasive 
pneumococcal disease and 82% (–155 to 100) against 
disease caused only by the six serotypes in PCV13 
additional to those in PCV7 (table 2), which was not 
signiﬁ cant. When including data for doses of PCV7 or 
PCV13 over the whole study period, adjusted vaccine 
eﬀ ectiveness against PCV7-serotype invasive pneumo-
coccal disease overall was lower than in the PCV13 
period (17%, 95% CI –304 to 80) and was not signiﬁ cant 
(table 3). Moreover, adjusted estimates of vaccine 
eﬀ ectiveness were negative for children with HIV 
infection and severe immunosuppression compared 
with those without severe immunosuppression and in 
those with malnutrition, but numbers in each subgroup 
for these analyses were small and diﬀ erences were not 
signiﬁ cant (table 3).
Discussion
Our analysis shows that two priming doses of PCV13 given 
in a 2 + 1 schedule are eﬀ ective against PCV13-serotype 
invasive pneumococcal disease in children not infected 
with HIV in a low-to-middle income African setting. 
We also found that the vaccine eﬀ ectiveness in 
two important risk groups—children not infected with 
HIV with malnutrition and children exposed to HIV but 
not infected—was high and similar to that in children 
without these conditions. These data provide evidence to 
support the ongoing introduction and sustained use of 
pneumococcal conjugate vaccine in low-income and 
middle-income countries.
PCV13 was licensed on the basis of immunogenicity 
data; therefore, data for vaccine eﬀ ectiveness against 
disease are especially important. Findings of a case-
control study from the UK, using an indirect cohort 
approach, showed that two doses of PCV13 in the ﬁ rst 
Unadjusted vaccine eﬀ ectiveness 
(95% CI)
Adjusted vaccine eﬀ ectiveness 
(95% CI)*
Children aged ≥16 weeks not infected with HIV
Overall 83% (61 to 92) 78% (46 to 91)
Exposed to HIV 91% (60 to 98) 87% (38 to 97)
Not exposed to HIV 81% (51 to 93) 82% (44 to 94)
Malnourished 85% (44 to 96) 90% (53 to 98)
Not malnourished 81% (40 to 94) 77% (17 to 94)
Children aged ≥16 weeks with HIV infection
Overall 26% (–98 to 72) 17% (–304 to 80)
Severe immunosuppression† –42% (–723 to 76) –104% (–1433 to 73)
No severe immunosuppression 75% (–31 to 95) 66% (–94 to 94)
Malnourished –40% (–390 to 60) –23% (–454 to 73)
Not malnourished 70% (–140 to 96) –7% (–3420 to 97)
Vaccine eﬀ ectiveness is shown for subgroups for which cases and controls were not matched (HIV exposure, malnutrition, 
severe immunosuppression) and was assessed by inclusion of an interaction term for the subgroup of interest in the 
multivariable model. For subgroup analyses, 25 discordant sets were identiﬁ ed in individuals not infected with HIV 
(25 included in the analysis of HIV exposure and 24 in the analysis of malnutrition). For subgroup analyses, 18 discordant 
sets were identiﬁ ed in individuals with HIV infection (14 included in the analysis of severe immunosuppression and 17 in the 
analysis of malnutrition). *For children not infected with HIV, adjustments were for whether the patient had received three 
doses of diphtheria, tetanus, and pertussis vaccine at 16 weeks of age and presence of crowding in the home. For children 
with HIV infection, adjustments were for receipt of antiretroviral therapy and presence of severe immunosuppression on 
CD4+ T-cell count. †Based on CD4+ percentage of total lymphocyte cell count, according to WHO categories.18
Table 3: Eﬀ ectiveness of two or more doses of PCV7 or PCV13 versus no doses against PCV7-serotype 
invasive pneumococcal disease over the full study period (March, 2010, to December, 2014) 
Discordant 
sets (n)
Unadjusted vaccine 
eﬀ ectiveness (95% CI)
Adjusted vaccine 
eﬀ ectiveness (95% CI)*
Children aged ≥16 weeks not infected with HIV
PCV13 serotypes (all)† 11 93% (71 to 98) 85% (37 to 96)
PCV13 serotypes (additional)‡ 6 95% (66 to 69) 92% (40 to 99)
PCV7 serotypes 5 89% (11 to 99) 74% (–183 to 98)
All serotypes 26 67% (29 to 85) 52% (–12 to 79)
Non-PCV13 serotypes 15 30% (–114 to 78) 15% (–189 to 75)
Meningitis PCV13 serotypes 4 94% (20 to 100) 75% (–875 to 100)
Bacteraemic pneumonia PCV13 serotypes 6 89% (28 to 98) 66% (–148 to 95)
Children aged ≥16 weeks with HIV infection
PCV13 serotypes (all)† 3 94% (20 to 100) 91% (–35 to 100)
PCV13 serotypes (additional)‡ 3 97% (55 to 100) 82% (–155 to 100)
PCV7 serotypes 0 NE NE
All serotypes 9 43% (–138 to 87) 3% (–1630 to 93)
Non-PCV13 serotypes 6 –107% (–1679 to 76) –558% (NE to 51)
Data are for two or more doses versus no doses. Discordant sets are when at least one control diﬀ ers from the case 
with respect to PCV13 vaccination status.NE=not estimable. *For children not infected with HIV, adjustments were 
for malnutrition, whether the patient had received three doses of diphtheria, tetanus, and pertussis vaccine at 
16 weeks of age, and maternal education level. For children with HIV infection, adjustments were for receipt of 
trimethoprim-sulfamethoxazole prophylaxis, receipt of antiretroviral therapy, and presence of severe 
immunosuppression on CD4+ T-cell count. †Serotypes in PCV13 were 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 
and 23F. ‡Additional serotypes in PCV13 but not in PCV7 were 1, 3, 5, 6A, 7F, and 19A.
Table 2: Eﬀ ectiveness of two or more doses of PCV13 versus no doses against invasive pneumococcal 
disease in children eligible to receive PCV13 through the routine immunisation programme (born after 
August, 2011), by pneumococcal serotype group and syndrome 
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year of life was 78% (95% CI –18 to 95) eﬀ ective against 
PCV13-serotype invasive pneumococcal disease.6 
Moreover, in a case-control study from the USA, 
one dose or more of PCV13 was 89% (95% CI 79 to 94) 
eﬀ ective against pneumococcal conjugate vaccine-
serotype invasive pneumococcal disease.8 Similar to 
these estimates, we found two or more doses of PCV13 
to be 85% (95% CI 37 to 96) eﬀ ective in children not 
infected with HIV. Our ﬁ ndings concur with results 
showing a substantial reduction in incidence of PCV13-
serotype disease in South African children younger than 
5 years after introduction of PCV13 in 2011.5
The point estimate for vaccine eﬀ ectiveness against 
all-serotype invasive pneumococcal disease in children 
not infected with HIV was 52% (95% CI –12 to 79), 
similar to the 60% eﬀ ectiveness seen in the USA (95% CI 
46·8–70·3), but this ﬁ nding was not signiﬁ cant on 
adjusted analysis.8 In children with HIV infection, the 
vaccine was also not eﬀ ective against all-serotype invasive 
pneumococcal disease serotypes (3% adjusted, 95% CI 
–1630 to 93). A major contributing factor to the inability 
to measure signiﬁ cant eﬀ ectiveness against all serotypes 
of invasive pneumococcal disease is probably that this 
study was done several years after the introduction of 
pneumococcal conjugate vaccine in South Africa, when 
vaccine serotypes had already become uncommon 
because of herd eﬀ ects, reducing their proportionate 
contribution to all cases of invasive pneumococcal 
disease. Additional contributing factors could include 
possible residual confounding and insuﬃ  cient power 
with available case numbers, particularly in the group 
with HIV infection.
Study ﬁ ndings suggest that vaccine eﬀ ectiveness might 
vary according to the serotype included in PCV13.7 
We documented high PCV13 eﬀ ectiveness against 
serotype 19A in children not infected with HIV, an 
important cause of replacement disease (ie, disease 
caused by non-vaccine serotypes that become relatively 
more common after vaccine introduction) in South Africa 
and globally.5 Although not signiﬁ cant, the point estimate 
of vaccine eﬀ ectiveness was high for serotype 1, an 
important cause of epidemic disease in low-income and 
middle-income countries and for which eﬃ  cacy studies 
have not shown protection conclusively.19 The pooled 
analysis from the PCV7 and PCV13 periods showed high 
vaccine eﬀ ectiveness against serotypes 14 and 23F. 
In studies from other settings, a high vaccine 
eﬀ ectiveness has been noted against serotypes 6B and 
19F; we observed low point estimates for vaccine 
eﬀ ectiveness but these did not reach signiﬁ cance because 
of the small sample size.20,21 Serotype replacement with 
non-vaccine serotypes is an important concern. 
Reassuringly in our study, we did not note negative 
vaccine eﬀ ectiveness against non-PCV13 serotypes 
(adjusted 15%, 95% CI –189 to 75).
In children with HIV infection, the high vaccine 
eﬀ ectiveness point estimate for two or more doses of 
PCV13 against PCV13-serotype invasive pneumococcal 
disease did not reach signiﬁ cance (91%, 95% CI –35 to 
100). This point estimate result diﬀ ered from that of our 
PCV7 vaccine eﬀ ectiveness assessment in children with 
HIV infection using the same approach in an earlier 
period (–12%, 95% CI –449 to 77).4 Recommendations for 
an additional 10-week dose of pneumococcal conjugate 
vaccine for children with HIV infection, made as a result 
of our earlier analysis,4 were never eﬀ ected because of 
programmatic challenges of implementing a diﬀ erent 
vaccine schedule in children infected with HIV and in 
those uninfected. Diﬀ ering vaccine eﬀ ectiveness point 
estimates could reﬂ ect uncertainty because of the low 
sample size, or improve ments in the general health status 
of infants infected with HIV in South Africa over time, 
leading to diﬀ erences in immunological responses to 
vaccination. Indeed, ﬁ ndings of a subgroup analysis 
found lower point estimates of eﬀ ectiveness in severely 
immuno suppressed and malnourished children with 
HIV infection, although these were not signiﬁ cant. 
Importantly, data for the eﬀ ect of pneumococcal conjugate 
vaccine show that children with HIV infection had striking 
reductions in incidence of invasive pneumococcal disease 
after implementation of pneumococcal conjugate vaccine.5
Children exposed to HIV but not infected make up 
approximately a third of babies born every year in 
South Africa; they have a high frequency of invasive 
pneumococcal disease and in-hospital mortality from the 
disease.22,23 PCV13 was eﬀ ective against PCV7-serotype 
invasive pneumococcal disease in these children from 
the PCV7 and PCV13 period, conﬁ rming earlier PCV7 
ﬁ ndings.4 Malnutrition is another common risk condition 
for invasive pneumococcal disease with severe outcomes 
in low-income and middle-income countries.24 Our study 
provides the ﬁ rst indication of eﬀ ectiveness of invasive 
pneumococcal disease in malnourished children not 
infected with HIV.
Our study had several limitations. Numbers of cases 
and controls with HIV infection were low and diminished 
over the study period because of eﬀ ective interventions for 
prevention of mother-to-child HIV transmission. Thus, 
we had to enrol controls with HIV infection at HIV clinics, 
potentially biasing estimates of vaccine eﬀ ectiveness 
upwards because children at HIV clinics might have 
better access to vaccination, even though we only included 
clinics that did not provide immunisation with 
pneumococcal conjugate vaccine. Controls enrolled at 
hospitals and clinics rather than in the community could 
diﬀ er in their vaccination status from the general 
population. Furthermore, the relatively high vaccination 
coverage in the population meant that few case-control 
pairs were discordant for vaccination status, even in 
children not infected with HIV. These low numbers led to 
wide conﬁ dence intervals for some estimates, particularly 
the analyses in individuals with HIV infection overall and 
by subgroup. Moreover, among the group not infected 
with HIV, for less speciﬁ c endpoints such as all-serotype 
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invasive pneumococcal disease and syndrome-speciﬁ c 
analyses, conﬁ dence intervals were wide after adjustment 
for potential confounders. These wide conﬁ dence intervals 
limit the precision of results and caution should be used 
when interpreting the point estimates. Because our study 
was done at sentinel surveillance sites nationally, it is 
possible that cases might not be representative of all cases 
of invasive pneumococcal disease in South Africa. It is 
also possible that vaccination status was misclassiﬁ ed; 
however, veriﬁ ed vaccination history for all included cases 
and controls was obtained and few were excluded based 
on unavailable vaccine history. The inclusion of children 
with diarrhoea as controls in a period of rotavirus vaccine 
availability could potentially have biased estimates towards 
a lower vaccine eﬀ ectiveness because controls with 
rotavirus might have been more likely to be unvaccinated. 
However, ﬁ ndings of a previous case-control study from 
South Africa showed that exclusion of patients positive for 
rotavirus with diarrhoea as potential controls did not 
change estimates of vaccine eﬀ ectiveness.25 In the adjusted 
analysis for children not infected with HIV, we included 
receipt of three doses of diphtheria, tetanus, and pertussis 
vaccine as a confounder in the multivariable model. 
Although it is not biologically plausible that this vaccine 
would directly aﬀ ect the risk of invasive pneumococcal 
disease, its inclusion resulted in substantial changes in 
the vaccine eﬀ ectiveness (lowering point estimates). The 
likely explanation is that receipt of the diphtheria, tetanus, 
and pertussis vaccine is a proxy for unmeasured 
confounders related to access to health care, which are 
important to control for. Importantly, we excluded 
collinearity between receipt of diphtheria, tetanus, and 
pertussis vaccine and pneumococcal conjugate vaccine.
In conclusion, we show that PCV13 as administered in 
the South African EPI in a 2 + 1 schedule is eﬀ ective 
against invasive pneumococcal disease caused by PCV13 
serotypes in children not infected with HIV. We also 
show that pneumococcal conjugate vaccine is eﬀ ective 
in children exposed to HIV but not infected and in 
malnourished children—two important risk groups for 
pneumococcal disease in low-income and middle-
income countries. We were unable to conclusively assess 
vaccine eﬀ ectiveness in children with HIV infection; 
however, data from impact studies of pneumococcal 
conjugate vaccine show that incidence of invasive 
pneumococcal disease in children with HIV infection 
has decreased substantially as a result of the introduction 
of pneumococcal conjugate vaccine.5 The relative 
contribution of direct and indirect eﬀ ects to this 
reduction is unclear. This study provides important data 
for eﬀ ectiveness of pneumococcal conjugate vaccine to 
the South African Department of Health and contributes 
to our understanding of the eﬀ ect of PCV13 in routine 
immunisation programmes in low-income and middle-
income countries.4 These study results contribute to the 
evidence base for pneumococcal conjugate vaccine 
dosing schedules and for programme sustainability.
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